PACIFIC Itch Study
Share this page

Latest News

The PBC Foundation is the only UK based organisation that specifically deals with PBC.

PACIFIC Itch Study

PACIFIC Itch Study

The PACIFIC study is currently enrolling participants with itch (pruritus) associated with cholestatic liver diseases such as Primary Biliary Cholangitis (PBC) or Primary Sclerosing Cholangitis (PSC).

To take part, you must:

• Be 18-80 years old

• Have a diagnosis of PBC or PSC

• Be experiencing moderate to severe itch related to cholestatic liver disease

About the study drug
How itch occurs in patients with liver disease is not fully understood. However, when the liver isn’t working properly, researchers believe that chemicals can build up in the skin, where they may activate a receptor that causes itch. EP547 is a new investigational treatment designed to block the receptor that causes itch. EP547 is not intended to improve the liver disease associated with PBC or PSC, but rather to help reduce the itch that liver disease can cause. EP547 is an investigational drug, which means it is not approved by any health authorities and is only available through participation in a clinical study like the PACIFIC study.

For more information, please visit PACIFICitchstudy.com or download the Pacific Itch Study leaflet here.

In this section

News Archive